Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

Infection. 2017 Feb;45(1):115-117. doi: 10.1007/s15010-016-0944-5. Epub 2016 Sep 26.

Abstract

Introduction: Ceftolozane/tazobactam is a novel antibiotic approved for the treatment of complicated intra-abdominal and complicated urinary tract infections.

Case description: We describe the use of off-label ceftolozane/tazobactam in the management of a multidrug-resistant Pseudomonas aeruginosa bacteremia that was already being treated with colistin and amikacin, the only active antibiotics according to the antibiogram.

Keywords: Bacteremia; Ceftolozane/tazobactam; Multidrug-resistant Pseudomonas aeruginosa.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia* / drug therapy
  • Bacteremia* / epidemiology
  • Bacteremia* / microbiology
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use*
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Off-Label Use
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / pharmacology
  • Penicillanic Acid / therapeutic use
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas Infections* / epidemiology
  • Pseudomonas Infections* / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Tazobactam

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftolozane
  • Penicillanic Acid
  • Tazobactam